These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 11020235)

  • 1. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
    Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
    Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
    Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
    Duttaroy A; Yoburn BC
    Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid receptor regulation in mice.
    Yoburn BC; Billings B; Duttaroy A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
    Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
    Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H; Wang X; Wang J; Rothman RB
    Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase A maintains cellular tolerance to mu opioid receptor agonists in hypothalamic neurosecretory cells with chronic morphine treatment: convergence on a common pathway with estrogen in modulating mu opioid receptor/effector coupling.
    Wagner EJ; Rønnekleiv OK; Kelly MJ
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1266-73. PubMed ID: 9618432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
    Stafford K; Gomes AB; Shen J; Yoburn BC
    Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA; Navani DM; Yoburn BC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
    Zhang Q; Purohit V; Yoburn BC
    Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
    Patel MB; Patel CN; Rajashekara V; Yoburn BC
    Mol Pharmacol; 2002 Dec; 62(6):1464-70. PubMed ID: 12435815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
    Gomes BA; Shen J; Stafford K; Patel M; Yoburn BC
    Pharmacol Biochem Behav; 2002 May; 72(1-2):273-8. PubMed ID: 11900797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
    Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
    Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
    Wong CS; Su YF; Watkins WD; Chang KJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):317-26. PubMed ID: 1320689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons.
    Rodríguez-Muñoz M; de la Torre-Madrid E; Gaitán G; Sánchez-Blázquez P; Garzón J
    Cell Signal; 2007 Dec; 19(12):2558-71. PubMed ID: 17825524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase C-mediated acute tolerance to peripheral mu-opioid analgesia in the bradykinin-nociception test in mice.
    Inoue M; Ueda H
    J Pharmacol Exp Ther; 2000 May; 293(2):662-9. PubMed ID: 10773042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antisense oligonucleotide to the N-methyl-D-aspartate (NMDA) subunit NMDAR1 attenuates NMDA-induced nociception, hyperalgesia, and morphine tolerance.
    Shimoyama N; Shimoyama M; Davis AM; Monaghan DT; Inturrisi CE
    J Pharmacol Exp Ther; 2005 Feb; 312(2):834-40. PubMed ID: 15388787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.